Teva Starts The Year With Phase III Data And Growth

 
• By Jessica Merrill

Teva reported positive Phase III data for a long-acting version of olanzapine for schizophrenia, coinciding with its first quarter sales and earnings release.

schizophrenia
Teva announced positive Phase III data for a long-acting version of olanzapine • Source: Shutterstock

More from Earnings

More from Business